(Q41634295)

5 October 2017

title

Interactions of the hepatitis C virus protease inhibitor faldaprevir with cytochrome P450 enzymes: in vitro and in vivo correlation (English)

1 reference

5 October 2017

1 reference

6

Manuel Battegay

1 reference

5 October 2017

4

Angela D M Kashuba

1 reference

5 October 2017

John P Sabo

1

1 reference

5 October 2017

Jens Kort

2

1 reference

5 October 2017

Charles Ballow

3

1 reference

5 October 2017

Manuel Haschke

5

1 reference

5 October 2017

Birgit Girlich

7

1 reference

5 October 2017

Naitee Ting

8

1 reference

5 October 2017

Benjamin Lang

9

1 reference

5 October 2017

Wei Zhang

10

1 reference

5 October 2017

Curtis Cooper

11

1 reference

5 October 2017

Drané O'Brien

12

1 reference

5 October 2017

Eleanore Seibert

13

1 reference

5 October 2017

Tom S Chan

14

1 reference

5 October 2017

Donald Tweedie

15

1 reference

5 October 2017

Yongmei Li

16

1 reference

5 October 2017

publication date

14 January 2015

1 reference

The Journal of Clinical Pharmacology

5 October 2017

published in

1 reference

5 October 2017

volume

55

1 reference

5 October 2017

issue

4

1 reference

5 October 2017

page(s)

467-477

1 reference

Preclinical Characterization of BI 201335, a C-Terminal Carboxylic Acid Inhibitor of the Hepatitis C Virus NS3-NS4A Protease

5 October 2017

cites work

1 reference

Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection

21 January 2018

1 reference

Faldaprevir combined with peginterferon alfa-2a and ribavirin in chronic hepatitis C virus genotype-1 patients with prior nonresponse: SILEN-C2 trial.

21 January 2018

1 reference

Faldaprevir combined with pegylated interferon alfa-2a and ribavirin in treatment-naïve patients with chronic genotype 1 HCV: SILEN-C1 trial.

21 January 2018

1 reference

SILEN-C3, a phase 2 randomized trial with faldaprevir plus pegylated interferon α-2a and ribavirin in treatment-naive hepatitis C virus genotype 1-infected patients

21 January 2018

1 reference

An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases

21 January 2018

1 reference

Enzyme-transporter interplay in the formation and clearance of abundant metabolites of faldaprevir found in excreta but not in circulation.

21 January 2018

1 reference

The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity

21 January 2018

1 reference

Comparison of different algorithms for predicting clinical drug-drug interactions, based on the use of CYP3A4 in vitro data: predictions of compounds as precipitants of interaction

21 January 2018

1 reference

Safety and efficacy of faldaprevir with pegylated interferon alfa-2a and ribavirin in Japanese patients with chronic genotype-1 hepatitis C infection

21 January 2018

1 reference

The Conduct of In Vitro and In Vivo Drug-Drug Interaction Studies: A PhRMA Perspective

21 January 2018

1 reference

Mechanism-based inactivation of CYP3A by HIV protease inhibitors

21 January 2018

1 reference

Combined phenotypic assessment of cytochrome p450 1A2, 2C9, 2C19, 2D6, and 3A, N-acetyltransferase-2, and xanthine oxidase activities with the "Cooperstown 5+1 cocktail".

21 January 2018

1 reference

Tolbutamide, flurbiprofen, and losartan as probes of CYP2C9 activity in humans

21 January 2018

1 reference

The effect of single- and multiple-dose etravirine on a drug cocktail of representative cytochrome P450 probes and digoxin in healthy subjects

21 January 2018

1 reference

A phenotype-genotype approach to predicting CYP450 and P-glycoprotein drug interactions with the mixed inhibitor/inducer tipranavir/ritonavir

21 January 2018

1 reference

Clinical management of drug-drug interactions in HCV therapy: challenges and solutions

21 January 2018

1 reference

Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/JCPH.436

1 reference

5 October 2017

1 reference